Erratum: Elevated serum gastrin is associated with a history of advanced neoplasia in barrett's esophagus (The American Journal of Gastroenterology (2009) DOI: 10.1038/ajg.2009.629);Elevated serum gastrin is associated with a history of advanced neoplasia in barrett's esophagus

American Journal of Gastroenterology

Volumn 105, Issue 5, 2010, Pages 1039-1045

  Wang, Judy S ^a   Varro, Andrea ^b   Lightdale, Charles J ^c,d   Lertkowit, Nantaporn ^b   Slack, Kristen N ^c   Fingerhood, Michael L ^c   Tsai, Wei Yann ^d,e,f   Wang, Timothy C ^c,d   Abrams, Julian A ^c,d  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e National Cheng Kung University ^*  (United States)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; PROTON PUMP INHIBITOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; DYSPLASIA; FEMALE; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 77951977553     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.723     Document Type: Erratum

References (47)

1. Ronkainen J, Aro P, Storskrubb T et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1825-1831
2. Conio M, Cameron AJ, Romero Y et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001; 48: 304-309
3. Cameron AJ, Zinsmeister AR, Ballard DJ et al. Prevalence of columnarlined (Barrett's) esophagus. Comparison of population-based clinical and autopsy fi ndings. Gastroenterology 1990; 99: 918-922
4. El-Serag H. Role of obesity in GORD-related disorders. Gut 2008; 57: 281-284
5. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555
6. Nocon M, Labenz J, Jaspersen D et al. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care-results from the ProGERD study. Aliment Pharmacol Ther 2007; 25: 715-722
7. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientifi c review. JAMA 2002; 287: 1972-1981
8. Lagergren J, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
9. Jansen JB, Klinkenberg-Knol EC, Meuwissen SG et al. Effect of longterm treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990; 99: 621-628
10. Ferrand A, Wang TC. Gastrin and cancer: a review. Cancer Lett 2006; 238: 15-29.
11. Haigh CR, Attwood SE, Th ompson DG et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003; 124: 615-625
12. Harris JC, Clarke PA, Awan A et al. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 2004; 64: 1915-1919
13. Moore TC, Jepeal LI, Boylan MO et al. Gastrin stimulates receptormediated proliferation of human esophageal adenocarcinoma cells. Regul Pept 2004; 120: 195-203.
14. Abdalla SI, Lao-Sirieix P, Novelli MR et al. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 2004; 10: 4784-4792
15. Morris CD, Armstrong GR, Bigley G et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96: 990-996
16. Georgopoulos SD, Polymeros D, Triantafyllou K et al. Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion 2006; 74: 42-46
17. Thorburn CM, Friedman GD, Dickinson CJ et al. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998; 115: 275-280
18. Furuta T, Shirai N, Sugimoto M et al. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5: 181-202.
19. Nemeth J, Varro A, Bridson J et al. Increased tissue concentrations of the gastrin precursor in patients treated with omeprazole. Eur J Clin Invest 1992; 22: 638-644
20. Monkemuller K, Neumann H, Nocon M et al. Serum gastrin and pepsinogens do not correlate with the diff erent grades of severity of gastrooesophageal reflux disease: a matched case-control study. Aliment Pharmacol Ther 2008; 28: 491-496
21. Yang YX, Hennessy S, Propert K et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007; 133: 748-754
22. Robertson DJ, Larsson H, Friis S et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007; 133: 755-760
23. Hillman LC, Chiragakis L, Shadbolt B et al. Eff ect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther 2008; 27: 321-326
24. El-Serag HB, Aguirre TV, Davis S et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-1883
25. Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006; 55: 1538-1544
26. Eissele R, Brunner G, Simon B et al. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-717
27. Avidan B, Sonnenberg A, Schnell TG et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 1930-1936
28. Vigneri S, Termini R, Leandro G et al. A comparison of fi ve maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-1110
29. Marks RD, Richter JE, Rizzo J et al. Omeprazole vs. H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907-915
30. Souza RF, Shewmake K, Pearson S et al. Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol 2004; 287: G743-8.
31. Souza RF, Shewmake K, Terada LS et al. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002; 122: 299-307.
32. Hao Y, Sood S, Triadafi lopoulos G et al. Gene expression changes associated with Barrett's esophagus and Barrett's-associated adenocarcinoma cell lines aft er acid or bile salt exposure. BMC Gastroenterol 2007; 7: 24.
33. Morgan C, Alazawi W, Sirieix P et al. In vitro acid exposure has a diff erential eff ect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line. Am J Gastroenterol 2004; 99: 218-224
34. Feagins LA, Zhang HY, Hormi-Carver K et al. Acid has antiproliferative eff ects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol 2007; 102: 10-20.
35. Zhang HY, Zhang X, Hormi-Carver K et al. In non-neoplastic Barrett's epithelial cells, acid exerts early antiproliferative eff ects through activation of the Chk2 pathway. Cancer Res 2007; 67: 8580-8587
36. Fitzgerald RC, Omary MB, Triadafi lopoulos G. Dynamic eff ects of acid on Barrett's esophagus. An ex vivo proliferation and diff erentiation model. J Clin Invest 1996; 98: 2120-2128
37. Ouatu-Lascar R, Fitzgerald RC, Triadafi lopoulos G. Diff erentiation and proliferation in Barrett's esophagus and the eff ects of acid suppression. Gastroenterology 1999; 117: 327-335
38. Umansky M, Yasui W, Hallak A et al. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 2001; 20: 7987-7991
39. Lao-Sirieix P, Roy A, Worrall C et al. Eff ect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 288-293
40. Shirvani VN, Ouatu-Lascar R, Kaur BS et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487-496
41. Wilson KT, Fu S, Ramanujam KS et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929-2934
42. Mehta S, Boddy A, Johnson IT et al. Systematic review: cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. Aliment Pharmacol Ther 2006; 24: 1321-1331
43. Kaur BS, Khamnehei N, Iravani M et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 60-67
44. Souza RF, Shewmake K, Beer DG et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000; 60: 5767-5772
45. Buttar NS, Wang KK, Anderson MA et al. The eff ect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst 2002; 94: 422-429
46. Buttar NS, Wang KK, Leontovich O et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122: 1101-1112
47. Subramaniam D, Ramalingam S, May R et al. Gastrin-mediated interleukin-8 and cyclooxygenase-2 gene expression: diff erential transcriptional and posttranscriptional mechanisms. Gastroenterology 2008; 134: 1070-1082